๐๐ฅ๐ข๐ก ๐ฆ๐ง๐จ๐๐ฌ
ุจุณู ุงููู ุงูุฑุญู ู ุงูุฑุญูู ุงูููู ุตู ุนูู ู ุญู ุฏ ูุขู ู ุญู ุฏ ู ุญุชูู ุงูููุงุฉ: ุดุฑูุญุงุช ุตูุฏูุฉ ุนุถููุฉ ู ุฑุญูุฉ ุซุงููุฉ ููุฑุณ ุซุงูู ูุงุฑู ุง ู ุฑุญูุฉ ุซุงูุซุฉ ููุฑุณ ุซุงูู ูุงุฑู ุง ู ุฑุญูุฉ ุฑุงุจุนุฉ ููุฑุณ ุงูู ูุงุฑู ุง ู ุฑุญูุฉ ุฑุงุจุนุฉ ููุฑุณ ุซุงูู ุนูุงุฌูุงุช ู ุฑุญูุฉ ุฎุงู ุณุฉ ููุชูุงุตู: @AronX2bot
Ko'proq ko'rsatish๐ Telegram kanali ๐๐ฅ๐ข๐ก ๐ฆ๐ง๐จ๐๐ฌ analitikasi
๐๐ฅ๐ข๐ก ๐ฆ๐ง๐จ๐๐ฌ (@aronstudy) Arab til segmentidagi kanali faol ishtirokchi. Hozirda hamjamiyat 13 339 obunachidan iborat bo'lib, Tibbiyot toifasida 1 928-o'rinni va Saudiya Arabistoni mintaqasida 5 694-o'rinni egallagan.
๐ Auditoriya koโrsatkichlari va dinamika
ะฝะตะฒัะดะพะผะพ sanasidan buyon loyiha tez oโsib, 13 339 obunachiga ega boโldi.
28 Iyun, 2026 dagi oxirgi maโlumotlarga koโra kanal barqaror faollikka ega. Oxirgi 30 kunda obunachilar soni 196 ga, soโnggi 24 soatda esa -18 ga oโzgardi va umumiy qamrov yuqori darajada qolmoqda.
- Tasdiqlash holati: Tasdiqlanmagan
- Jalb etish (ER): Auditoriya oโrtacha 27.91% darajada jalb etiladi. Nashrdan keyingi dastlabki 24 soatda kontent odatda umumiy obunachilar sonining 9.87% ini tashkil etuvchi reaksiyalarni toโplaydi.
- Post qamrovi: Har bir post oโrtacha 3 727 marta koโriladi; birinchi sutkada odatda 1 318 ta koโrish yigโiladi.
- Reaksiyalar va oโzaro taโsir: Auditoriya faol: har bir postga oโrtacha 36 ta reaksiya keladi.
- Tematik yoโnalishlar: Kontent ู ูุงุฏููุฉ, ุทูุงููุจ, ุงูุณุชูุจูููุงู, ุณูููุงู , ุฑูุณูุงููุฉ kabi asosiy mavzularga jamlangan.
๐ Tavsif va kontent siyosati
Muallif resursni shaxsiy fikrni ifoda etish maydoni sifatida taโriflaydi:
โุจุณู
ุงููู ุงูุฑุญู
ู ุงูุฑุญูู
ุงูููู
ุตู ุนูู ู
ุญู
ุฏ ูุขู ู
ุญู
ุฏ
ู
ุญุชูู ุงูููุงุฉ:
ุดุฑูุญุงุช ุตูุฏูุฉ
ุนุถููุฉ ู
ุฑุญูุฉ ุซุงููุฉ ููุฑุณ ุซุงูู
ูุงุฑู
ุง ู
ุฑุญูุฉ ุซุงูุซุฉ ููุฑุณ ุซุงูู
ูุงุฑู
ุง ู
ุฑุญูุฉ ุฑุงุจุนุฉ ููุฑุณ ุงูู
ูุงุฑู
ุง ู
ุฑุญูุฉ ุฑุงุจุนุฉ ููุฑุณ ุซุงูู
ุนูุงุฌูุงุช ู
ุฑุญูุฉ ุฎุงู
ุณุฉ
ููุชูุงุตู:
@AronX2botโ
Yuqori yangilanish chastotasi (oxirgi maโlumot 29 Iyun, 2026 da olingan) sababli kanal doimo dolzarb va katta qamrovli boโlib qoladi. Analitika auditoriya kontent bilan faol hamkorlik qilishini, uni Tibbiyot toifasidagi muhim taโsir nuqtasiga aylantirishini koโrsatadi.
Chemotherapy: ๐ธClofarabine โ active in refractory acute leukemias ๐นBlinatumomab โ targets CD19, for Ph negative relapsed or refractory ALL ๐ธInotuzumab ozogamicin โ anti CD-22, used in relapsed and refractory B-ALL ๐นTisagenlecleucel โ anti-CD19, used in patients with relapsed and refractory B-cell ALL#Leukemia ๐๐ฅ๐ข๐ก ๐ฆ๐ง๐จ๐๐ฌ
5 elements: Induction CNS directed Treatment Consolidation Reinduction Maintenance phase
1. Induction Therapy: vincristine L- asparaginase steroid (prednisone or dexamethasone) ุงู Dexamethazone ูู ุงูู ูุถู ูุงู ููุฏุฑ ููุตู ูู CNS ู ู ฺฉู ุจุงูู higher risk patient ูุถูู ุฏูุงุก ู ู ู ุฌู ูุนุฉ anthracycline
2. CNS prophylaxis: A. Intrathecal: Cytarabine MTX Steroid B. Systemic chemotherapy: Dexamethasone high-dose methotrexate ุจุงูุงุถุงูุฉ ุงูู ุงูุฃุดุนุงุน craniospinal irradiation (XRT) in selected high-risk patients (T-cell ALL)
3. Consolidation High dose of chemotherapy 4. Reinduction A. Interim maintenance 2 months B. Delayed intensification for 3 months after remission ููุณ ุงุฏููุฉ ุงู induction ูุนูุฏูุง ู ู ุฌุฏูุฏ 5. Maintenance phase oral methotrexate 6- mercaptopurine. 2-3 years with low dose#Leukemia ๐๐ฅ๐ข๐ก ๐ฆ๐ง๐จ๐๐ฌ
Endi mavjud! Telegram Tadqiqoti 2025 โ yilning asosiy insaytlari 
